(WOUND COllagen Managment)
Colzyx develops a novel innovative wound matrix, WOUNDCOM, where the company’s proprietary bioactive molecules are used a surface coating. Here, these molecules are called Effector-molecules. WOUNDCOM is the prioritized product to be developed by Colzyx.
Molecules used for wound matrix coating today are based on inorganic or small molecules. In contrast, Colzyx WOUNDCOM project is utilizing Effectors molecules which are bioactive parts from the biological host-defense protein human collagen VI, which has evolved to initiate, stimulate and control normal physiological wound healing processes as well exhibiting clear antimicrobial effects. Thus, Colzyx Effector molecules have both a pronounced wound-healing effect as well as a broad-spectrum antimicrobial effect, against both normal and multidrug resistant bacteria.
Colzyx´ Effectors are derived from human collagen VI and exhibit a naturally evolved biological activity as compared to inorganic or small molecules. In addition, due to its human origin Colzyx´ Effector is anticipated to have excellent safety and toxicology profiles.
- Mediate accelerated wound healing effect
- Prevent persistent wound infections and subsequent biofilm formation
- Remove existing biofilm and render bacteria susceptible to antimicrobial treatment
- Mediate antimicrobial effect, including multi resistant bacteria
- Adjust the level of inflammation
- Reduce pain
Colzyx is the first company to utilize molecules derived from human collagen VI for this purpose which provides a unique position.
Patient - benefits